Following aducanumab, lecanemab, and other amyloid immunotherapies likely to follow, treatments targeting progranulin for frontotemporal dementia (FTD) may be among the next round of disease-modifying neurodegenerative disease therapeutics. This evidence concerns the gene GRN and neurodegenerative disease.